Scilex Holding Company

SCLX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Revenue $30.3M $56.6M $46.7M $38.0M $31.3M $23.6M
Cost of Revenue $10.6M $16.7M $15.7M $10.8M $3.6M $2.1M
Gross Profit $125.8M $167.4M $31.1M $27.2M $27.7M $21.4M
Gross Margin 415.8% 295.8% 66.5% 71.6% 88.4% 90.9%
Operating Expenses
Research & Development $20.7M $9.6M $12.7M $9.1M $9.2M $10.0M
SG&A Expense $266.9M $119.0M $119.6M $64.9M $50.6M $43.0M
Operating Income $-346.0M $-83.4M $-105.4M $-50.6M $-35.8M $-35.3M
Operating Margin -1,143.7% -147.4% -225.6% -133.1% -114.4% -149.7%
Interest Expense $1.1M $9.6M $11.8M $13.1M
Pretax Income $-374.0M $-72.8M $-114.3M $-23.4M $-88.4M $-47.6M
Income Tax Expense $26.0K $-1.0K $13.0K $4.0K $5.0K $-53.0K
Net Income $-374.1M $-72.8M $-114.3M $-23.4M $-88.4M $-47.5M
Net Margin -1,236.4% -128.7% -244.6% -61.4% -282.4% -201.7%
EPS (Basic) $-36.48 $-7.24 $-1.28 $-0.17 $-0.67 $0.00
EPS (Diluted) $-36.48 $-8.05 $-1.28 $-0.17 $-0.67 $0.00
Shares Outstanding (Basic) 11.0K 131.1M 130.3M 134.2M 132.9M 132.9M
Shares Outstanding (Diluted) 11.0K 134.1M 130.3M 134.2M 132.9M 132.9M
Dividends Per Share